Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
NCT ID: NCT00788294
Last Updated: 2020-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
76 participants
INTERVENTIONAL
2008-11-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects
NCT05028127
A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
NCT00997919
A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
NCT04255862
XmAb5871 Bioavailability Study
NCT02867098
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
NCT01367496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10 mg IV
tanezumab
Drug solution given intravenously only once at dose of 10 mg
5 mg SC
tanezumab
Drug solution given subcutaneously only once at dose of 5 mg.
10 mg SC
tanezumab
Drug solution given subcutaneously only once at dose of 10 mg.
19 mg SC
tanezumab
Drug solution given subcutaneously only once at dose of 19 mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tanezumab
Drug solution given intravenously only once at dose of 10 mg
tanezumab
Drug solution given subcutaneously only once at dose of 5 mg.
tanezumab
Drug solution given subcutaneously only once at dose of 10 mg.
tanezumab
Drug solution given subcutaneously only once at dose of 19 mg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of 18-30 kg/m2
* more than 50 kg bodyweight.
Exclusion Criteria
* exposure to biologic type drugs within the last 3 months
* history of allergic or anaphylactic reaction to a biologic drug
* use of tobacco- or nicotine containing products that is more than what is in 5 cigarettes per day
* excessive alcohol use.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Cypress, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A4091013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.